Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esomeprazole + levosulpiride
- Development stage
- Unknown
- Lead developer
- ARB Remedies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EZICO-L is a fixed-dose combination small molecule pharmaceutical developed by ARB Remedies for the treatment of gastroesophageal reflux disease (GERD). It consists of esomeprazole, a proton pump inhibitor (PPI), and levosulpiride, a prokinetic agent. Esomeprazole reduces gastric acid secretion by covalently binding to and irreversibly inhibiting the H+/K+ ATPase enzyme system (the proton pump) in the gastric parietal cells. Levosulpiride acts as a selective antagonist at dopamine D2 and D3 receptors in the gastrointestinal tract, which enhances the release of acetylcholine, thereby increasing lower esophageal sphincter tone and promoting gastric emptying. This dual mechanism addresses both acid overproduction and impaired motility, providing relief from symptoms such as heartburn and regurgitation. The product is approved and marketed in capsule form, typically featuring a sustained-release formulation of levosulpiride.
- Brand names
- EZICO-L
- Other names
- Esomeprazole and Levosulpiride SR Capsules
02
Targets
HTR4 (5-Hydroxytryptamine receptor 4)DRD2 (Dopamine D2 Receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on esomeprazole + levosulpiride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esomeprazole + levosulpiride.